Q4 2024 Hikal Ltd Earnings Call Transcript
Key Points
- Sequential revenue increase of 15% to INR514 crore and EBITDA increase of 45% to INR94 crore.
- Full year FY24 revenue stood at INR1,785 crore with EBITDA margins at 15%, an increase of 230 basis points.
- FDA audit of API facility in Panoli, Gujarat concluded with zero 483 observations.
- Commissioning of new multi-purpose plant for animal health at Panoli with several product validations completed.
- Strong pipeline of projects within the CDMO space and active pursuit of additional opportunities.
- Current operating environment marked by inventory backlog, oversupply, and heightened price competition in the crop protection industry.
- Global crop protection industry continues to face significant headwinds, including subdued global demand and intense price competition.
- Destocking situation continues to impact demand globally, with improvements expected only towards the end of FY25.
- Asset turns have decreased to 1.1 to 1.3 times due to increased CapEx and infrastructure investments.
- ROCE has dropped in the last two to three years, with expectations to improve only once full capacity utilization is achieved.
Ladies and gentlemen, good day, and welcome to Hikal Limited Q4 FY24 earnings conference call. This conference call may contain forward-looking statements about the company, which are based on beliefs opinions and expectations of the company as on the date of this call.
These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Sameer Hiremath from Managing Director. Thank you, and over to you, sir.
Thank you. Good afternoon, ladies and gentlemen, and welcome to Hikal's Q4 and FY24 results conference call. We are pleased to provide you with an update on the progress made by your company. We trust that you have had the opportunity to review our comprehensive earnings release, financial statements and the investor presentation for the quarter and financial year ended March 31
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
